MY199104A - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Info

Publication number
MY199104A
MY199104A MYPI2019003348A MYPI2019003348A MY199104A MY 199104 A MY199104 A MY 199104A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY PI2019003348 A MYPI2019003348 A MY PI2019003348A MY 199104 A MY199104 A MY 199104A
Authority
MY
Malaysia
Prior art keywords
bipolar disorder
alleviation
prevention
treatment
carbamate compounds
Prior art date
Application number
MYPI2019003348A
Other languages
English (en)
Inventor
Yu Jin Shin
Sei Myoung Han
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MY199104A publication Critical patent/MY199104A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019003348A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder MY199104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MY199104A true MY199104A (en) 2023-10-13

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003348A MY199104A (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28529A (id) * 1997-08-14 2001-05-31 Hoffmann La Roche Vinileter heterosiklik untuk gangguan neurologi
US6555585B2 (en) 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Also Published As

Publication number Publication date
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
AU2017374458A1 (en) 2019-07-04
ES3054693T3 (en) 2026-02-05
AU2017374458B2 (en) 2023-03-02
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
CA3046297A1 (en) 2018-06-21
EP3556366B1 (en) 2025-10-22
CL2019001618A1 (es) 2019-08-23
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR102635938B1 (ko) 2024-02-13
MX2019006940A (es) 2019-09-06
ZA201903747B (en) 2021-01-27
RU2019121913A3 (enExample) 2021-04-21
JP7208139B2 (ja) 2023-01-18
KR20190087572A (ko) 2019-07-24
CN110290788A (zh) 2019-09-27
EP3556366A1 (en) 2019-10-23
IL267195A (enExample) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
PH12021500034A1 (en) Compounds useful in hiv therapy
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MY197698A (en) Oxysterols and methods of use thereof
MX395482B (es) Compuestos antiproliferativos y metodos de uso de los mismos
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MY202884A (en) Compounds useful in hiv therapy
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
SG11201803867TA (en) Sodium channel blocker
PH12020550549A1 (en) Compositions for preventing or treating lupus
MY198417A (en) Use of Carbamate Compound for Preventing, Alleviating, or Treating Tremors or Tremor Syndrome